, Tracking Stock Market Picks
Enter Symbol:

up 65.44 %

MASIMO CORP (MASI) rated Outperform with price target $29 by Boenning & Scattergood

Posted on: Thursday,  May 6, 2010  10:25 AM ET by Boenning & Scattergood

Boenning & Scattergood rated Outperform MASIMO CORP (NASDAQ: MASI) on 05/06/2010, when the stock price was $25.47. Since
then, MASIMO CORP has gained 65.45% as of 08/27/2015's recent price of $42.14.
If you would have followed this Boenning & Scattergood's recommendation on MASI, you would have gained 65.44% of your investment in 1939 days.

Masimo develops innovative monitoring technologies that significantly improve patient care -- helping solve `unsolvable` problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry's ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of `Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.`

Our equity research team concentrates on companies that aren’t widely covered in sectors such as water distribution/equipment/technology, financial services, business services, aerospace & defense technology, medical technology and retail.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/6/2010 10:25 AM Buy
25.47 29.00
as of 12/31/2010
1 Week down  -5.09 %
1 Month down  -8.84 %
3 Months up  3.00 %
1 YTD up  10.44 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy